Currently Enrolling Trials
Galzin has been approved for the treatment of Wilson's disease. Wilson’s disease is a potentially fatal inherited abnormality, occurring in one of 30,000 people, that causes excess copper to accumulate in the body, affecting the liver and the brain. Patients become ill as teenagers or as young adults with liver disease, often with neurologic symptoms. Galzin works by blocking absorption of copper from the intestine.